Tag Archive for ‘Alliance for Clinical Trials in Oncology’
Three important trials examining adjuvant therapies for biliary tract cancers, which were recently completed and reported, are summarized.
Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results
The clinical importance of the Alliance A021101 cooperative group study as well as the design of the trial itself are the focus of this month’s column.
This column addresses the efficacy of combining existing approaches with active therapeutic combinations to treat cancers of the stomach and esophagus.
The rationale for neoadjuvant therapy is explored in this month’s column along with a summary of Alliance clinical trials involving this treatment.
Older adults are projected to comprise a significant portion of a surgeon’s patient population. However, current surgical oncology trials are not designed to allow for widespread generalizability to their practice. This column features insights into the gap between cancer trials and the real world and the potential role of Z901101 in stimulating future studies and polices to broaden the accrual of older adults and their surgeons in new oncology trials.
This column discusses how multimodality therapy, including surgical resection, now represents a potential route to long-term survival for a group of patients with so-called “borderline resectable” cancers.
The American College of Surgeons Oncology Group (ACOSOG), the Cancer and Leukemia Group B (CALGB), and the North Central Cancer Treatment Group (NCCTG) recently merged to form the Alliance for Clinical Trials in Oncology.